Drugs / GEM103
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04246866 | Dec 2019 → Oct 2020 | diffuse secondary choroid atrophy, dry age related macular degeneration | Gemini Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04684394 | Dec 2020 → Jan 2022 | wet macular degeneration | Gemini Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04643886 | Jul 2020 → Feb 2022 | diffuse secondary choroid atrophy, dry age related macular degeneration | Gemini Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEM103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04684394 ↗ |
| Known as | Recombinant Human Complement Factor H | “A Phase I, Single Ascending Dose Study of GEM103 (Recombinant Human Complement Factor H) in Patients with Geographic Atrophy.” PMID 36249705 ↗ Apr 2022 |
| Action | Restore | “pharmacodynamic data suggesting that GEM103 restored complement regulation” PMID 36249705 ↗ Apr 2022 |
| Modality | Protein / enzyme biologic | “GEM103 (Recombinant Human Complement Factor H)” PMID 36249705 ↗ Apr 2022 |
| Route | Intravitreal | “intravitreal injection” NCT04246866 ↗ |